Regulus Therapeutics Inc. announced that new pre-clinical data from multiple therapeutic programs were presented at the "RNA Silencing: Mechanism, Biology and Application" Keystone Symposium held January 14 - 19, 2010 in Keystone, Colorado. Regulus and its collaborators presented data showing microRNA target regulation by anti-miRs, as well as data from therapeutic programs focused on oncology, immune disease and hepatitis C virus (HCV) infection. "The field of microRNA discovery and therapeutic development is growing exponentially and at a tipping point," said Peter S. Linsley, Ph.D...
More...
More...